Bonum Therapeutics
Shannon Okada is a highly experienced Principal Scientist with a robust focus on immuno-oncology and biotherapeutics, currently serving at Bonum Therapeutics since September 2022. Prior roles include Principal Scientist at Good Therapeutics, Inc. and Senior Scientist at Bristol-Myers Squibb, where significant contributions were made in establishing methods for myeloid-derived suppressor cells (MDSCs) and target validation strategies for cancer treatment. Shannon's industry experience spans a variety of research domains, including preclinical research at ZymoGenetics and contract research at MDS Pharma Services, with a strong foundation in organic chemistry and biochemistry obtained from the University of Washington and the University of Notre Dame, respectively.
Bonum Therapeutics
Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management.